|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-1-3
|
|
pubmed:abstractText |
Topotecan has demonstrated exceptional central nervous system penetration as well as radiosensitizing properties in glioblastoma xenografts [Chastagner et al., Int J Radiat Oncol Biol Phy 50: 777-782, 2001]. This phase I trial was performed to determine the maximum tolerated dose and the recommended dose of topotecan continuous infusion administered together with concomitant radiotherapy in patients with glioblastoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0167-594X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
269-75
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12510778-Adult,
pubmed-meshheading:12510778-Aged,
pubmed-meshheading:12510778-Antineoplastic Agents,
pubmed-meshheading:12510778-Central Nervous System Neoplasms,
pubmed-meshheading:12510778-Combined Modality Therapy,
pubmed-meshheading:12510778-Glioblastoma,
pubmed-meshheading:12510778-Humans,
pubmed-meshheading:12510778-Infusions, Intravenous,
pubmed-meshheading:12510778-Maximum Tolerated Dose,
pubmed-meshheading:12510778-Middle Aged,
pubmed-meshheading:12510778-Neutropenia,
pubmed-meshheading:12510778-Radiotherapy, Conformal,
pubmed-meshheading:12510778-Sepsis,
pubmed-meshheading:12510778-Sinusitis,
pubmed-meshheading:12510778-Thrombocytopenia,
pubmed-meshheading:12510778-Topotecan
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study.
|
|
pubmed:affiliation |
Department of Radiation Oncology, University Hospitals of Erlangen-Nürnberg, Erlangen, Germany. gerd.grabenbauer@strahlen.imed.uni-erlangen.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
